GlassScriptPhysician profile
George G Gubernikoff
NPI 1447246988
$4,638.67
in general payments reported to CMS, 2019-2025
24 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $214 · 2021: $570 · 2022: $837 · 2023: $1,339 · 2024: $755 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $776.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $629.41 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $469.89 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $430.95 | 2019-2023 | Lifevest |
| Amgen INC. | $363.66 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.03 | 2021-2025 | Jardiance |
| Abbott Laboratories | $278.97 | 2022-2023 | Amplatzer Amulet, Cardiomems, Mitraclip |
| Pfizer INC. | $229.05 | 2022-2025 | |
| Medtronic Vascular, INC. | $211.51 | 2019 | |
| Medtronic, INC. | $145.90 | 2023-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $115.44 | 2024 | Watchman Flx |
| Kestra Medical Technology Services, INC. | $113.59 | 2023 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $99.37 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $91.23 | 2023-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $65.90 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $50.73 | 2021-2024 | Farxiga |
| Chiesi USA, INC. | $50.40 | 2020-2023 | Kengreal, Cleviprex |
| Siemens Medical Solutions USA, INC. | $31.43 | 2020-2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Genzyme Corporation | $27.20 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.97 | 2025 | |
| Scpharmaceuticals INC. | $22.17 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.09 | 2021 | |
| Esperion Therapeutics, INC. | $15.86 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.31 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gubernikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.